Theriva Biologics has announced that clinical and preclinical data from its Phase 1 trial of VCN-01 (zabilugene almadenorepvec) in refractory intraocular retinoblastoma will be presented in an invited session at the 2026 Asia-Pacific Academy of Ophthalmology Congress in Hong Kong. The presentation includes safety data from two intravitreal injections in children who had exhausted all other treatment options, alongside preclinical evidence showing enhanced antitumor activity when VCN-01 is combined with the chemotherapeutic topotecan.

How VCN-01 reframes the therapeutic ceiling in pediatric patients resistant to conventional ocular chemotherapy

Children with intraocular retinoblastoma that proves refractory to standard chemotherapy—whether systemic, intra-arterial, or intravitreal—face a narrow and unforgiving set of options. In many cases, the only remaining intervention is enucleation, a drastic surgical procedure that carries permanent physical and psychosocial consequences. Theriva Biologics is testing whether VCN-01 can shift that paradigm by delivering tumor-selective viral activity directly into the eye, targeting microscopic vitreous seeds that are notoriously chemotherapy-resistant.

The intravitreal route allows VCN-01 to exploit the eye’s immune-privileged compartment, reducing systemic toxicity while enabling local viral replication. The virus also degrades hyaluronic acid, potentially enhancing penetration into tumor matrices. Pediatric oncologists note that this strategy may go beyond preservation of the globe—it could help preserve vision, psychological health, and long-term function in a patient group where every avoided surgery represents a meaningful clinical win.

Why new synergy data with topotecan may influence combination regimen planning in next-stage trial designs

Theriva’s preclinical synergy data linking VCN-01 to improved topotecan efficacy is emerging as a more disruptive finding than the Phase 1 safety signals alone. Topotecan is a backbone drug in current intravitreal chemotherapy protocols but suffers from variable efficacy against vitreous seeds, particularly in heavily pretreated cases. The observed enhancement when co-administered with VCN-01 could reflect a biologically synergistic mechanism—possibly through local matrix remodeling, viral priming of tumor cells, or disruption of the tumor’s immune cloaking.

Investigators tracking pediatric ocular oncology suggest this opens the door to a new class of rationally designed viral-chemotherapy pairings. Such combinations could potentially reduce required chemotherapy dosing while improving cytotoxicity, preserving retinal tissue, and delaying the need for enucleation. In future trials, this could also support flexible protocol designs—such as crossover arms or dose-adaptive regimens—based on tumor morphology and vitreous seeding patterns.

What rare pediatric and orphan designations reveal about regulatory optionality and potential voucher leverage

The trial’s small-scale design—just two intravitreal injections in a high-risk population—signals a safety-first approach. But Theriva Biologics has already secured both Orphan Drug and Rare Pediatric Disease designations for VCN-01 in this indication. These bring not only potential exclusivity and tax benefits but also the chance for a Priority Review Voucher (PRV), a valuable asset that can be sold or redeemed for faster regulatory review of other programs.

Regulatory strategists suggest that if a pivotal study demonstrates clear improvements in ocular salvage or disease stabilization in the absence of enucleation, regulators may be receptive to accelerated pathways. Agencies are increasingly open to alternative endpoints—such as tumor regression combined with visual acuity retention or delay of surgical intervention—particularly in rare pediatric settings. For Theriva, the key challenge will lie in validating early efficacy signals with reproducible clinical impact in a broader cohort while sustaining safety across multiple injections.

How APAO 2026 exposure can catalyze global clinical engagement in a highly regionalized disease landscape

Theriva’s selection for an APAO 2026 invited session elevates its visibility among a geographically diverse and disease-specialized audience. Retinoblastoma incidence and treatment capacity vary widely across Asia-Pacific, Latin America, and Africa, with notable disparities in access to enucleation alternatives. The presence of co-presenters from Sant Joan de Déu-Barcelona Children’s Hospital also reinforces the growing international interest in moving beyond chemotherapy-only regimens.

Clinicians attending APAO will be acutely focused on practical issues—such as viral dosing precision, ophthalmic injection training, post-injection monitoring protocols, and immune suppression risks in pediatric patients. If Theriva succeeds in demonstrating operational feasibility within diverse hospital settings, this could accelerate uptake into compassionate use or expanded access pathways even before formal approval. Global investigator networks may also begin to evaluate VCN-01’s relevance across subtypes, such as group D/E retinoblastoma or unilateral versus bilateral disease.

How VCN-01’s tumor-directed viral replication model differentiates from other localized biologics in pediatric oncology

VCN-01 is engineered to selectively replicate in tumor cells with high retinoblastoma protein (pRB) pathway disruption, making it well-suited for malignancies like retinoblastoma that originate from pRB loss. This makes it mechanistically distinct from non-specific chemotherapeutics and provides potential specificity advantages over radiation or non-replicating gene therapies. The added feature of hyaluronidase expression—designed to break down extracellular matrix and improve viral diffusion—gives VCN-01 a dual-action profile uncommon among other pediatric intravitreal candidates.

Few other investigational products in pediatric ocular cancer combine these features with a localized delivery mechanism. Emerging academic virotherapy programs remain largely preclinical, often focused on gliomas or systemic neuroblastoma, without adapting to the anatomic and procedural realities of ophthalmic administration. Theriva’s integration of mechanistic targeting, compartmentalized delivery, and chemotherapy compatibility positions VCN-01 as a candidate with differentiated therapeutic logic rather than repackaged oncology tropes.

What implementation and immunogenicity hurdles could still delay broader adoption across treatment centers

Despite its strengths, VCN-01’s pathway to adoption is neither automatic nor low-risk. Pediatric retinal specialists remain cautious about potential immunogenic responses to repeated adenoviral injections, particularly given the limited precedent in young children. Even transient vitritis, intraocular inflammation, or changes in intraocular pressure could compromise vision in an already fragile organ.

From a systems standpoint, reliable production and cold-chain delivery of live viral vectors remain non-trivial—especially for under-resourced hospitals or clinics operating without GMP-grade storage infrastructure. The procedural burden of intravitreal injections in children under anesthesia also introduces scheduling, sedation, and reimbursement complexities that require protocol standardization across centers.

Theriva’s upcoming regulatory interactions will likely need to address these delivery, repeatability, and safety surveillance concerns directly—especially if the pivotal study includes real-world endpoints or multi-arm combination regimens. Failure to do so could constrain the drug’s potential to large academic centers with advanced ophthalmic oncology programs.

Why VCN-01 is emblematic of a broader push toward biologic compartmentalization in early pediatric treatment

VCN-01 reflects a growing strategic shift within pediatric oncology: designing biologics to exploit anatomical compartments as therapeutic ecosystems. In contrast to systemic exposure models, compartmentalized delivery can yield higher local drug concentrations, faster onset of action, and reduced toxicity. Retinoblastoma, with its distinct ocular boundaries and immune landscape, represents an ideal test bed for this emerging logic.

If Theriva demonstrates proof of concept with VCN-01, it could inform biologic strategies for other compartmentalized indications such as medulloblastoma (CSF), Ewing’s sarcoma (pleura), or peritoneal rhabdomyosarcoma. The question then becomes how companies balance biologic complexity, delivery feasibility, and compartment access while ensuring safety in ultra-young patient populations. As of APAO 2026, Theriva may be the furthest along in answering that question with data—not just promise.

  APAO 2026, intravitreal therapy, oncolytic virus, pediatric oncology, retinoblastoma, Theriva Biologics, topotecan, VCN-01, zabilugene almadenorepvec